Puma Biotechnology has out-licensed rights to develop and commercialize its breast cancer therapy Nerlynx (neratinib) to France’s Pierre Fabre. The agreement covers Europe and parts of Africa. 3 April 2019
Chordia Therapeutics, a Kanagawa, Japan-based oncology startup has raised $27 million in a series B financing round. The firm was spun out of Takeda Pharmaceutical in late 2017, and previously raised $11 million. 1 April 2019
AstraZeneca and Merck & Co have been granted Breakthrough Therapy Designation (BTD) for selumetinib, a MEK 1/2 inhibitor the firms are developing as a treatment for certain children with plexiform neurofibromas (PN), a rare and incurable genetic condition. 1 April 2019
Japan’s Chugai Pharmaceutical and Fuji Chemical Industries have entered into a business transfer agreement for Ulcerlmin (sucralfate hydrate) for the treatment of gastritis/peptic ulcer, now manufactured and marketed by Chugai. 1 April 2019
Danish diabetes care giant Novo Nordisk today announced plans to invest 650 million Danish kroner ($98.5 million) in upgrading and expanding facilities at its production site in Kalundborg, Denmark. 29 March 2019
Best known as the maker of Botox (onabotulinumtoxinA), Ireland-headquartered Allergan today announced it has completed the acquisition of Envy Medical, a privately held company with proprietary technology in skin resurfacing. 27 March 2019
Ukranian drug discovery services firm Enamine has agreed terms for a deal with CNS specialist Lundbeck for an expansion of an existing research collaboration. 26 March 2019
The anti-epilepsy drug Vimpat IV infusion 200mg (lacosamide) has been launched in Japan by the drug’s developer Belgium drugmaker UCB and Japanese partner Daiichi Sankyo. 26 March 2019
China’s HitGen and Spain’s Almirall have agreed terms for a research collaboration to leverage the former’s DNA-encoded library design, synthesis and screening technology to isolate novel small molecule leads for targets of interest. 26 March 2019
Japan’s Kyowa Hakko Kirin and London-listed AstraZeneca have expanded an existing licensing agreement, giving the latter exclusive rights to Fasenra (benralizumab) for all current and future indications in Asia. 25 March 2019
Takeda has been awarded a positive reimbursement decision in the UK regarding Adcetris (brentuximab vedotin) as a second-line therapy for certain people with advanced cutaneous T-cell lymphoma (CTCL). 22 March 2019
Oxford, UK-based artificial intelligence specialist Exscientia has set up a Japanese subsidiary in Osaka, led by Daisuke Tanaka, the former director of innovative chemistry at Sumitomo Dainippon. 22 March 2019
The US Department of Health and Human Services (HHS) yesterday released an additional $487 million to supplement first-year funding through its State Opioid Response (SOR) grant program. 21 March 2019
Japanese drugmaker Ono Pharmaceutical has submitted a supplemental application of Kyprolis (carfilzomib), a proteasome inhibitor, in Japan for additional dosage and administration for the treatment of relapsed or refractory multiple myeloma, as a partial change in approved items of the manufacturing and marketing approval. 20 March 2019
Spain’s Reig Jofre has begun marketing remifentanil, an in-hospital anesthetic, in the Korean market. The firm has now completed registration in Korea, following approval of a designated production plant by the Korean Food and Drug Administration (KFDA). 20 March 2019
Mundipharma has now launched Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin), two treatment options for the management of type 2 diabetes, in Norway. 19 March 2019
Japanese drugmaker Daiichi Sankyo has announced results from ELIMINATE-AF, a study comparing once-daily Lixiana (edoxaban) 60 mg to uninterrupted vitamin K antagonists (VKA) in atrial fibrillation (AF) patients undergoing catheter ablation. 18 March 2019
Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that AstraZeneca’s Farxiga (dapagliflozin) reduced the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo in patients with type-2 diabetes (T2D) who had a prior heart attack (myocardial infarction). 18 March 2019
Tokyo’s Chugai Pharmaceutical has filed for approval to market entrectinib in Japan for the treatment of certain people with non-small cell lung cancer (NSCLC). 15 March 2019
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024